Arca
Skip to content
Tools
Tools

T cell surface glycoprotein CD3

Complex in Homo sapiens that 16 drugs act on.

  • Drugs that act on it: 16
  • Approved: 10
  • In phases 1 to 3: 5
  • Sponsors: 8
  • Genes: 3

Who is on it, and how far along

Every drug ChEMBL records acting on CD3D, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 13
  • Other 3

Approved10

  • Blinatumomab
  • Glofitamab
  • Muromonab-CD3
  • Teclistamab
  • Epcoritamab
  • Elranatamab
  • Mosunetuzumab
  • Tarlatamab
  • Talquetamab
  • Catumaxomab

Phase 31

  • Odronextamab

Phase 23

  • Foralumab
  • Flotetuzumab
  • Solitomab

Phase 11

  • FBT-A05

Preclinical or unknown1

  • IMC-GP100

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

The landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 9 of 16 act as: T cell surface glycoprotein CD3 binding agent; the rest name their own mechanism.
BlinatumomabBoxed warningApprovedAmgenAntibodyCross-linking agentT cell surface glycoprotein CD3 cross-linking agent119
GlofitamabBoxed warningApprovedRocheAntibodyBinding agent89
Muromonab-CD3Boxed warningApprovedRegeneronOtherInhibitorT cell surface glycoprotein CD3 inhibitor85
TeclistamabBoxed warningApprovedJohnson & JohnsonAntibodyBinding agent66
EpcoritamabBoxed warningApprovedGenmabAntibodyBinding agent62
ElranatamabBoxed warningApprovedPfizerAntibodyBinding agent50
MosunetuzumabBoxed warningApprovedRocheAntibodyBinding agent48
TarlatamabApprovedAmgenAntibodyBinding agent39
TalquetamabBoxed warningApprovedJohnson & JohnsonAntibodyBinding agent38
CatumaxomabApprovedNeovii BiotechAntibodyCross-linking agentT cell surface glycoprotein CD3 cross-linking agent0
OdronextamabPhase 3RegeneronAntibodyBinding agent14
ForalumabPhase 2Tiziana Life SciencesAntibodyInhibitorT cell surface glycoprotein CD3 inhibitor5
FlotetuzumabPhase 2—AntibodyBinding agent1
SolitomabPhase 2—AntibodyCross-linking agentT cell surface glycoprotein CD3 cross-linking agent0
FBT-A05Phase 1—OtherCross-linking agentT cell surface glycoprotein CD3 cross-linking agent0
IMC-GP100Preclinical or unknown—OtherCross-linking agentT cell surface glycoprotein CD3 cross-linking agent0

Open trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 75 in all, from ClinicalTrials.gov.
A Trial of FHD-286 Plus Mosunetuzumab in Previously Treated Follicular LymphomaMosunetuzumabPhase 1Not yet recruitingWeill Medical College of Cornell UniversityNov 17, 2026
A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple MyelomaElranatamab—Not yet recruitingPfizerNov 9, 2026
Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALLBlinatumomabNot applicableNot yet recruitingInstitute of Hematology & Blood Diseases Hospital, ChinaNov 6, 2026
A Trial to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatment of Patients With DLBCL-type Richter TransformationEpcoritamabPhase 2RecruitingGerman CLL Study GroupNov 5, 2026
Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell LymphomaGlofitamabPhase 2Not yet recruitingM.D. Anderson Cancer CenterNov 5, 2026
Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaBlinatumomab, Muromonab-CD3Phase 1Not yet recruitingCity of Hope Medical CenterNov 3, 2026
Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan TrialMosunetuzumab, Muromonab-CD3Phase 2Not yet recruitingUniversity of WashingtonNov 2, 2026
A Study of CLEC2A CAR T for Pediatric and Adult Patients With Relapsed or Refractory AMLMuromonab-CD3Phase 1Not yet recruitingSeattle Children's HospitalOct 29, 2026
Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaElranatamabPhase 2Not yet recruitingPETHEMA FoundationOct 28, 2026
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Participants With Extensive Stage-Small Cell Lung CancerTarlatamabPhase 2Not yet recruitingAbbVieOct 26, 2026
RE-RITE: Real-world Evaluation of Response, Implementation and Toxicity of ElranatamabElranatamab—Not yet recruitingThe Royal Wolverhampton Hospitals NHS TrustOct 23, 2026
Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System LymphomaGlofitamabPhase 2Not yet recruitingThe First Affiliated Hospital with Nanjing Medical UniversityOct 22, 2026
Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaTalquetamab, TeclistamabPhase 2 / Phase 3Not yet recruitingAlliance for Clinical Trials in OncologyOct 22, 2026
Real-World Use of Tarlatamab in Chinese Patients With Small-Cell Lung CancerTarlatamab—Active, not recruitingRuijin HospitalOct 21, 2026
REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)Muromonab-CD3, OdronextamabPhase 1 / Phase 2Not yet recruitingRegeneron PharmaceuticalsOct 21, 2026
Epcoritamab as Consolidative Therapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a Bruton Tyrosine Kinase Inhibitor (BTKi)EpcoritamabPhase 2Not yet recruitingNational Heart, Lung, and Blood Institute (NHLBI)Oct 20, 2026
Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell LymphomasEpcoritamab, GlofitamabPhase 2RecruitingNational Research Center for Hematology, RussiaOct 20, 2026
A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard TreatmentsElranatamabPhase 4Not yet recruitingPfizerOct 19, 2026
BLinatumomab and iNKT in Relapsed B-Cell ALLBlinatumomabPhase 1Not yet recruitingUNC Lineberger Comprehensive Cancer CenterOct 9, 2026
A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Receiving Epcoritamab InjectionsEpcoritamab—Not yet recruitingAbbVieOct 7, 2026
Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Pirtobrutinib in Combination With Epcoritamab if the Disease Comes Back After Previous Treatment.EpcoritamabPhase 2Not yet recruitingStichting Hemato-Oncologie voor Volwassenen NederlandOct 6, 2026
Exploratory Study on the Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Severe Primary Sjögren's SyndromeBlinatumomabPhase 2Not yet recruitingBeijing Tongren HospitalOct 1, 2026
Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALLBlinatumomabPhase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, ChinaSep 25, 2026
Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKIEpcoritamabPhase 2Not yet recruitingUniversity of California, IrvineSep 14, 2026
Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell TherapyEpcoritamabPhase 2Not yet recruitingThe Lymphoma Academic Research OrganisationSep 10, 2026
Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance StatusTarlatamabPhase 2RecruitingAIO-Studien-gGmbHSep 4, 2026
Teclistamab In Waldenstrom's MacroglobulinemiaTeclistamabPhase 2Not yet recruitingMassachusetts General HospitalAug 28, 2026
Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple MyelomaElranatamabPhase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, ChinaAug 27, 2026
A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia AElranatamabNot applicableNot yet recruitingInstitute of Hematology & Blood Diseases Hospital, ChinaAug 26, 2026
Tarlatamab in Recurrent Gynecological Neuroendocrine Carcinomas: A Phase II Proof-of-concept StudyTarlatamabPhase 2Not yet recruitingUniversity Hospital, Strasbourg, FranceAug 26, 2026
Tarlatamab Treatment Before and After Surgery in Surgically Resectable Recurrent High-grade Glioma: a Window of Opportunity Study (TARLAGLIA Study)TarlatamabPhase 1Not yet recruitingVall d'Hebron Institute of OncologyAug 26, 2026
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphomaEpcoritamabPhase 2Not yet recruitingM.D. Anderson Cancer CenterAug 25, 2026
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)TarlatamabPhase 3RecruitingAmgenAug 21, 2026
Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell LymphomaGlofitamabPhase 2Not yet recruitingThe First Affiliated Hospital of Soochow UniversityAug 19, 2026
Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.TeclistamabPhase 2Not yet recruitingOdense University HospitalAug 11, 2026
Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCLGlofitamabPhase 2RecruitingThe First Affiliated Hospital of Xiamen UniversityAug 6, 2026
Glofitamab in B-NHL Using Mid-Therapy Intratumoral TranscriptomicsGlofitamabPhase 2Not yet recruitingJoshua BrodyAug 5, 2026
A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable DiseaseTalquetamab, TeclistamabPhase 3Not yet recruitingPolish Myeloma ConsortiumJul 31, 2026
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple MyelomaTeclistamabPhase 3RecruitingAbbVieJul 27, 2026
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit LymphomaGlofitamab, Muromonab-CD3Phase 2 / Phase 3RecruitingNational Cancer Institute (NCI)Jul 24, 2026
A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALLBlinatumomabPhase 3Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, ChinaJul 23, 2026
TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)TalquetamabPhase 1Not yet recruitingMontefiore Medical CenterJul 22, 2026
AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCLGlofitamabPhase 2Not yet recruitingRuijin HospitalJul 21, 2026
Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) as Conditioning Regimen for ABO-incompatible Living Donor Kidney TransplantationBlinatumomab, TeclistamabEarly phase 1Not yet recruitingWest China HospitalJul 15, 2026
A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)TarlatamabPhase 2Not yet recruitingUniversity of CologneJul 13, 2026
Safety and Efficacy of BiTE in Desensitization Therapy for Highly Sensitized Kidney Transplant Candidates With cPRA ≥ 90%Blinatumomab, TeclistamabPhase 4Not yet recruitingWest China HospitalJul 8, 2026
The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal ForalumabForalumab, Muromonab-CD3Phase 2Enrolling by invitationTiziana Life Sciences LTDJul 7, 2026
Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare CancersMuromonab-CD3Phase 2Not yet recruitingNational Cancer Institute (NCI)Jul 7, 2026
GMMG-HD11/DSMM XXI/64007957MMY3010TeclistamabPhase 3Not yet recruitingUniversity of Heidelberg Medical CenterJun 26, 2026
Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory MyelomaTalquetamab, Muromonab-CD3Phase 2RecruitingNaresh BummaJun 18, 2026
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelTalquetamabPhase 3RecruitingUniversity of LeedsJun 16, 2026
HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIVElranatamabPhase 1RecruitingUniversity of Illinois ChicagoJun 15, 2026
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple MyelomaElranatamabPhase 2RecruitingSCRI Development Innovations, LLCJun 10, 2026
Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With TreatmentMosunetuzumabPhase 2Not yet recruitingSWOG Cancer Research NetworkJun 10, 2026
Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung CancerTarlatamabPhase 3Not yet recruitingPrECOG, LLC.Jun 9, 2026
A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus NephritisMosunetuzumabPhase 2RecruitingHoffmann-La RocheMay 20, 2026
Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple MyelomaTalquetamabPhase 1RecruitingChristopher StrouseMay 12, 2026
Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRDMosunetuzumabPhase 2RecruitingM.D. Anderson Cancer CenterMay 5, 2026
Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular LymphomaMosunetuzumabPhase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, ChinaApr 29, 2026
Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)MosunetuzumabPhase 2Not yet recruitingUniversity of UtahApr 23, 2026
Talquetamab in Patients With Refractory Generalized Myasthenia GravisTalquetamabNot applicableNot yet recruitingFirst Affiliated Hospital of Chongqing Medical UniversityMar 30, 2026
BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.TalquetamabPhase 4Not yet recruitingAnne Louise Tølbøll SørensenMar 16, 2026
Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).Mosunetuzumab—RecruitingAndrés José Maria FerreriDec 12, 2025
Odronextamab in Low Tumor Volume Advanced FLOdronextamabPhase 2RecruitingGottfried von Keudell, MD PhDAug 19, 2025
Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus NephritisOdronextamabPhase 1RecruitingRegeneron PharmaceuticalsMay 16, 2025
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple SclerosisForalumabPhase 2RecruitingTiziana Life Sciences LTDMar 24, 2025
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)ForalumabPhase 2RecruitingTiziana Life Sciences LTDMar 11, 2025
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell TherapyOdronextamabPhase 2RecruitingUniversity of California, DavisMar 3, 2025
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-TOdronextamabPhase 2RecruitingUniversity of WashingtonJan 20, 2025
Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's TransformationOdronextamabPhase 1RecruitingCity of Hope Medical CenterDec 16, 2024
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's DiseaseForalumabPhase 2RecruitingBrigham and Women's HospitalJul 8, 2024
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin LymphomaOdronextamabPhase 3Active, not recruitingRegeneron PharmaceuticalsJan 30, 2024
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone LymphomaOdronextamabPhase 3RecruitingRegeneron PharmaceuticalsNov 28, 2023
Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid LeukemiaFlotetuzumabPhase 1Active, not recruitingChildren's Oncology GroupNov 12, 2019
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric DiseasesForalumabPhase 1 / Phase 2RecruitingBrigham and Women's HospitalJan 8, 2016

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364168, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.